Gujarat Terce Laboratories Ltd Company Summary

Gujarat Terce Laboratories Limited, incorporated in 1985, is a trusted manufacturer of high quality medication at affordable rates for the common man. Company specialise in producing oral solid dosages, including tablets and capsules, that address various therapeutic needs.Headquartered in Ahmedabad, Gujarat, Terce offers an extensive portfolio featuring over 125 products and more than 64 well-established brands. By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.

In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange. In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat. As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.The Company offers products in the form of tablets, capsules, syrups, and injections.

The installed capacity of the Company is 270 million tablets and 108 million capsules per annum. It focuses on formulation improvements, new product development, and research to identify gaps in existing treatment options.The Company otherwise or hence maintains strict and controlled environment for manufacturing and adheres to Good Manufacturing Practices and Good Laboratory Practices to assure highest level of patient safety and outcome efficacy. It has well-defined Total Quality Management System in place to continuously optimize products and processes.

Each process is thoroughly monitored and data is collected for analysis which helps in planning corrective and preventive strategies for quality control. To serve the needs of patients and healthcare professionals, Company focus on early and rapid detection of diseases. Their team of scientists is supported by doctors, patients and marketing team in identifying pressing needs and developing solutions.

It has capabilities of innovation across generic drugs to complex formulations, biosimilars and new molecular entity.